CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for STADA Arzneimittel AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

STADA Arzneimittel AG
Stadastrasse 2-18
Phone: +49 61016030p:+49 61016030 Bad Vilbel, 61118  Germany Ticker: STDAFSTDAF
This company was Merged or Acquired on 3/31/2026.
This is a Subsidiary, click here for the Parent Company
Business Summary
STADA Arzneimittel AG is a Germany-based manufacturer of pharmaceuticals. The Company operates three business segments: Consumer Healthcare, Specialty Pharmaceuticals, and Generics. The Consumer Healthcare segment offers healthcare products for all categories includes cough and cold, derma, vitamins, minerals and gastro, pain and relief, women’s, and men's health through Nizoral, Zoflora, Grippostad, Silomat and Hirudoid brands. The Specialty pharmaceuticals segment delivers biological medicines, including biosimilars, offer treatment options for patients with chronic and disabling conditions including Cancer, osteoporosis, ophthalmic conditions and autoimmune diseases such as rheumatoid arthritis, Psoriasis and Crohn’s disease. The Generics segment is engaged in production and sales of inexpensive medicines that are known as generics. Its generic drugs are prescription products for the healthcare market that are sold under an International Nonproprietary Name (INN) brand.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Supervisory Board GuenterVon Au 74 9/25/2017 9/25/2017
Chairman of the Executive Board, Chief Executive Officer PeterGoldschmidt 61 9/1/2018 9/1/2018
Deputy Chairman of the Supervisory Board AndreaWende 57 6/1/2024 6/1/2024
11 additional Officers and Directors records available in full report.

Business Names
Business Name
0OM4
ALIUD PHARMA GmbH
AO Nizhpharm
112 additional Business Names available in full report.

General Information
Number of Employees: 11,540 (As of 6/30/2024)
Outstanding Shares: 62,258,167 (As of 6/30/2024)
Shareholders: 3,980
Stock Exchange: HAM
Fax Number: +49 6101603259


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 12, 2026